Lilly begins phase 3 trial of eloralintide as an add-on to weekly incretin drugs
The trial tests stacking a second drug on top of a weekly incretin for people who still have obesity on treatment, rather than switching medications.
Eli Lilly has begun enrolling a phase 3 trial of eloralintide, an experimental amylin drug, in adults who still have obesity or overweight while already taking a weekly incretin medicine [1].
The study, listed on ClinicalTrials.gov as NCT07392190, is titled "A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin" [1]. It is designed to enroll about 900 adults and to assign them at random to eloralintide or a placebo for roughly 80 weeks, with everyone continuing their existing weekly incretin [1]. Eloralintide is also known as LY3841136 [1].
Weekly incretins include semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound. The registry listing describes the background therapy only as "a weekly incretin," and it does not say which specific drug participants must already be taking [1].
Lilly's public pipeline lists eloralintide in phase 3 for obesity as a new molecular entity, and separately lists a phase 3 program called "Eloralintide Incretin Add-On" for obesity [2]. The same pipeline also lists eloralintide in phase 3 for obstructive sleep apnea and for osteoarthritis pain [2].
The trial design points toward a different strategy from the one that has dominated the obesity drug market so far. Instead of comparing two drugs head to head and asking patients to switch, this study holds the weekly incretin steady and adds a second drug on top of it for people whose weight has not come down enough on the incretin alone [1].
Several details have not been reported. The registry listing does not state the dose of eloralintide being tested, how it is given, which specific weekly incretin is required, or what the main outcome measure will be [1]. No results have been posted, and no completion date appears in the listing [1]. Eloralintide is not approved for any use.
Why it matters for patients
Many people who start a GLP-1 medication lose weight and then plateau, and some lose relatively little. This trial is aimed directly at that group: it enrolls only people whose obesity has persisted despite weekly incretin therapy [1]. If an add-on works, it could eventually give patients and doctors a choice that does not exist today, which is to keep the current medication and layer a second one on top rather than stopping and switching. The trial population is defined by having persistent obesity on treatment, but how many patients that describes has not been reported [1].
Nothing changes for patients now. Eloralintide is investigational, the trial is just starting, and no results exist yet [1]. Whether a future add-on would be covered by insurance, what it would cost, or how it would be administered are all unknown and have not been disclosed [1]. Adding a second drug would also mean additional side effects and, depending on how it is given, additional injections, but the trial has not reported safety data [1].
What happens next
The ENLIGHTEN-6 trial is enrolling about 900 adults, who will be followed for roughly 80 weeks of treatment [1]. Because of that length, meaningful results are not expected soon, and no readout date has been disclosed [1]. Lilly's pipeline continues to list eloralintide in phase 3 across obesity, obstructive sleep apnea and osteoarthritis pain, alongside the separate incretin add-on obesity program [2]. Until results are reported, it will not be known whether adding eloralintide to a weekly incretin helps people who have not reached their weight goals [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.